TWI529247B - 抗人類ｃｄ５２免疫球蛋白 - Google Patents

Info

Publication number

TWI529247B

TWI529247B TW099115371A TW99115371A TWI529247B TW I529247 B TWI529247 B TW I529247B TW 099115371 A TW099115371 A TW 099115371A TW 99115371 A TW99115371 A TW 99115371A TW I529247 B TWI529247 B TW I529247B

Authority

TW

Taiwan

Prior art keywords

seq

antibody

human

light chain

heavy chain

Prior art date

2009-05-13

Links

• Espacenet
• Global Dossier
• Discuss

• 108060003951 Immunoglobulin Proteins 0.000 title description 377
• 102000018358 immunoglobulin Human genes 0.000 title description 377
• 229940072221 immunoglobulins Drugs 0.000 title description 66
• 210000004027 cell Anatomy 0.000 claims description 364
• 101000980814 Homo sapiens CAMPATH-1 antigen Proteins 0.000 claims description 273
• 102000043738 human CD52 Human genes 0.000 claims description 264
• 230000027455 binding Effects 0.000 claims description 255
• 102000013135 CD52 Antigen Human genes 0.000 claims description 202
• 108010065524 CD52 Antigen Proteins 0.000 claims description 202
• 150000007523 nucleic acids Chemical class 0.000 claims description 166
• 102000039446 nucleic acids Human genes 0.000 claims description 158
• 108020004707 nucleic acids Proteins 0.000 claims description 158
• 238000000034 method Methods 0.000 claims description 139
• 241000282414 Homo sapiens Species 0.000 claims description 134
• 210000001744 T-lymphocyte Anatomy 0.000 claims description 132
• 102000036639 antigens Human genes 0.000 claims description 106
• 108091007433 antigens Proteins 0.000 claims description 106
• 210000003719 b-lymphocyte Anatomy 0.000 claims description 106
• 239000013598 vector Substances 0.000 claims description 105
• 239000000427 antigen Substances 0.000 claims description 103
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 75
• 108010076504 Protein Sorting Signals Proteins 0.000 claims description 44
• 206010028980 Neoplasm Diseases 0.000 claims description 42
• 210000002966 serum Anatomy 0.000 claims description 41
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 35
• 239000000203 mixture Substances 0.000 claims description 31
• 210000000822 natural killer cell Anatomy 0.000 claims description 29
• 238000006467 substitution reaction Methods 0.000 claims description 27
• 239000002773 nucleotide Substances 0.000 claims description 25
• 125000003729 nucleotide group Chemical group 0.000 claims description 25
• 201000011510 cancer Diseases 0.000 claims description 23
• 201000006417 multiple sclerosis Diseases 0.000 claims description 22
• 239000003814 drug Substances 0.000 claims description 19
• 208000023275 Autoimmune disease Diseases 0.000 claims description 18
• 210000000440 neutrophil Anatomy 0.000 claims description 18
• 230000002829 reductive effect Effects 0.000 claims description 17
• 210000003289 regulatory T cell Anatomy 0.000 claims description 15
• 238000012258 culturing Methods 0.000 claims description 14
• 108091028043 Nucleic acid sequence Proteins 0.000 claims description 13
• 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 12
• 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 12
• 230000003472 neutralizing effect Effects 0.000 claims description 10
• 238000002360 preparation method Methods 0.000 claims description 10
• 230000001850 reproductive effect Effects 0.000 claims description 10
• 230000004540 complement-dependent cytotoxicity Effects 0.000 claims description 9
• 235000004279 alanine Nutrition 0.000 claims description 7
• 230000033115 angiogenesis Effects 0.000 claims description 7
• 206010039073 rheumatoid arthritis Diseases 0.000 claims description 7
• 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 7
• 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 6
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 6
• 229960000548 alemtuzumab Drugs 0.000 claims description 6
• 239000002269 analeptic agent Substances 0.000 claims description 6
• 230000002401 inhibitory effect Effects 0.000 claims description 6
• 230000036210 malignancy Effects 0.000 claims description 5
• 206010047115 Vasculitis Diseases 0.000 claims description 4
• 230000001404 mediated effect Effects 0.000 claims description 4
• 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 3
• 230000001506 immunosuppresive effect Effects 0.000 claims description 3
• 230000001939 inductive effect Effects 0.000 claims description 3
• 208000032839 leukemia Diseases 0.000 claims description 3
• 206010025323 Lymphomas Diseases 0.000 claims description 2
• 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 2
• 230000002491 angiogenic effect Effects 0.000 claims description 2
• 239000000539 dimer Substances 0.000 claims description 2
• 230000004068 intracellular signaling Effects 0.000 claims description 2
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
• 206010062016 Immunosuppression Diseases 0.000 claims 1
• 208000004732 Systemic Vasculitis Diseases 0.000 claims 1
• 230000001737 promoting effect Effects 0.000 claims 1
• 230000008685 targeting Effects 0.000 claims 1
• 241000699666 Mus <mouse, genus> Species 0.000 description 210
• 102100024952 Protein CBFA2T1 Human genes 0.000 description 88
• 241000699670 Mus sp. Species 0.000 description 81
• 239000008280 blood Substances 0.000 description 81
• 210000004369 blood Anatomy 0.000 description 80
• 210000004698 lymphocyte Anatomy 0.000 description 78
• 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 77
• 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 77
• 229940112129 campath Drugs 0.000 description 73
• 210000000952 spleen Anatomy 0.000 description 64
• 108090000623 proteins and genes Proteins 0.000 description 60
• 238000011282 treatment Methods 0.000 description 56
• 238000011830 transgenic mouse model Methods 0.000 description 50
• 238000004458 analytical method Methods 0.000 description 41
• 102000004169 proteins and genes Human genes 0.000 description 40
• 230000000694 effects Effects 0.000 description 39
• 235000018102 proteins Nutrition 0.000 description 39
• 230000009870 specific binding Effects 0.000 description 39
• 241000699660 Mus musculus Species 0.000 description 38
• 238000000684 flow cytometry Methods 0.000 description 37
• 230000035772 mutation Effects 0.000 description 37
• 235000001014 amino acid Nutrition 0.000 description 36
• 238000003556 assay Methods 0.000 description 36
• 239000003053 toxin Substances 0.000 description 34
• 231100000765 toxin Toxicity 0.000 description 34
• 108700012359 toxins Proteins 0.000 description 34
• 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 33
• 102000015696 Interleukins Human genes 0.000 description 30
• 108010063738 Interleukins Proteins 0.000 description 30
• 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 29
• 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 29
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 28
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 28
• 108090000765 processed proteins & peptides Proteins 0.000 description 28
• 239000013604 expression vector Substances 0.000 description 26
• 230000002147 killing effect Effects 0.000 description 26
• 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 25
• 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 25
• 229940024606 amino acid Drugs 0.000 description 25
• 238000011156 evaluation Methods 0.000 description 25
• 239000012634 fragment Substances 0.000 description 25
• 210000004881 tumor cell Anatomy 0.000 description 25
• 150000001413 amino acids Chemical class 0.000 description 24
• 230000004083 survival effect Effects 0.000 description 24
• 238000004519 manufacturing process Methods 0.000 description 22
• 229940126619 mouse monoclonal antibody Drugs 0.000 description 22
• 230000004927 fusion Effects 0.000 description 20
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 20
• 102000004196 processed proteins & peptides Human genes 0.000 description 20
• 239000011651 chromium Substances 0.000 description 18
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
• 239000003795 chemical substances by application Substances 0.000 description 17
• 210000005259 peripheral blood Anatomy 0.000 description 17
• 239000011886 peripheral blood Substances 0.000 description 17
• 230000009089 cytolysis Effects 0.000 description 16
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 16
• 210000002443 helper t lymphocyte Anatomy 0.000 description 16
• 229920001184 polypeptide Polymers 0.000 description 16
• 238000012360 testing method Methods 0.000 description 16
• 201000010099 disease Diseases 0.000 description 15
• 239000002609 medium Substances 0.000 description 15
• 239000003981 vehicle Substances 0.000 description 15
• OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 14
• 108090001005 Interleukin-6 Proteins 0.000 description 14
• -1 phospholipid phosphoinositide lipid Chemical class 0.000 description 14
• 238000003752 polymerase chain reaction Methods 0.000 description 14
• 239000000523 sample Substances 0.000 description 14
• 230000002269 spontaneous effect Effects 0.000 description 14
• 102000004889 Interleukin-6 Human genes 0.000 description 13
• 210000000988 bone and bone Anatomy 0.000 description 12
• 239000012636 effector Substances 0.000 description 12
• 238000002474 experimental method Methods 0.000 description 12
• 210000004962 mammalian cell Anatomy 0.000 description 12
• 239000000872 buffer Substances 0.000 description 11
• 231100000673 dose–response relationship Toxicity 0.000 description 11
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 11
• 230000002441 reversible effect Effects 0.000 description 11
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 10
• 102000004127 Cytokines Human genes 0.000 description 10
• 108090000695 Cytokines Proteins 0.000 description 10
• 238000011534 incubation Methods 0.000 description 10
• 239000007924 injection Substances 0.000 description 10
• 238000002347 injection Methods 0.000 description 10
• 210000003519 mature b lymphocyte Anatomy 0.000 description 10
• 210000000066 myeloid cell Anatomy 0.000 description 10
• 239000006228 supernatant Substances 0.000 description 10
• 210000001519 tissue Anatomy 0.000 description 10
• 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 9
• 229940124296 CD52 monoclonal antibody Drugs 0.000 description 9
• 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 9
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 9
• 241001465754 Metazoa Species 0.000 description 9
• 241000700159 Rattus Species 0.000 description 9
• 238000009175 antibody therapy Methods 0.000 description 9
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 9
• 239000002299 complementary DNA Substances 0.000 description 9
• 239000012091 fetal bovine serum Substances 0.000 description 9
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 9
• 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 9
• 230000006870 function Effects 0.000 description 9
• 210000004989 spleen cell Anatomy 0.000 description 9
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
• NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 8
• 238000002965 ELISA Methods 0.000 description 8
• 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 description 8
• 101000716124 Homo sapiens T-cell surface glycoprotein CD1c Proteins 0.000 description 8
• 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 8
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 8
• 102100024219 T-cell surface glycoprotein CD1a Human genes 0.000 description 8
• 102100040247 Tumor necrosis factor Human genes 0.000 description 8
• 239000007767 bonding agent Substances 0.000 description 8
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 8
• 238000003776 cleavage reaction Methods 0.000 description 8
• 206010025135 lupus erythematosus Diseases 0.000 description 8
• 239000003550 marker Substances 0.000 description 8
• 230000004899 motility Effects 0.000 description 8
• 230000008569 process Effects 0.000 description 8
• 230000007017 scission Effects 0.000 description 8
• 239000011734 sodium Substances 0.000 description 8
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 7
• QWPXBEHQFHACTK-KZVYIGENSA-N (10e,12e)-86-chloro-12,14,4-trihydroxy-85,14-dimethoxy-33,2,7,10-tetramethyl-15,16-dihydro-14h-7-aza-1(6,4)-oxazina-3(2,3)-oxirana-8(1,3)-benzenacyclotetradecaphane-10,12-dien-6-one Chemical compound CN1C(=O)CC(O)C2(C)OC2C(C)C(OC(=O)N2)CC2(O)C(OC)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 QWPXBEHQFHACTK-KZVYIGENSA-N 0.000 description 7
• 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 7
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 7
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 7
• 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 description 7
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 7
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
• 239000013504 Triton X-100 Substances 0.000 description 7
• 229920004890 Triton X-100 Polymers 0.000 description 7
• 238000007792 addition Methods 0.000 description 7
• 229930195731 calicheamicin Natural products 0.000 description 7
• HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 7
• 125000000837 carbohydrate group Chemical group 0.000 description 7
• 230000000295 complement effect Effects 0.000 description 7
• 150000001875 compounds Chemical class 0.000 description 7
• 238000001514 detection method Methods 0.000 description 7
• 239000012153 distilled water Substances 0.000 description 7
• 210000001616 monocyte Anatomy 0.000 description 7
• 102000005962 receptors Human genes 0.000 description 7
• 108020003175 receptors Proteins 0.000 description 7
• 238000010186 staining Methods 0.000 description 7
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
• 101100505340 Arabidopsis thaliana GLY1 gene Proteins 0.000 description 6
• VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 6
• 102000004190 Enzymes Human genes 0.000 description 6
• 108090000790 Enzymes Proteins 0.000 description 6
• 102000006395 Globulins Human genes 0.000 description 6
• 108010044091 Globulins Proteins 0.000 description 6
• 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 6
• 101100383049 Homo sapiens CD52 gene Proteins 0.000 description 6
• 125000000539 amino acid group Chemical group 0.000 description 6
• 235000003704 aspartic acid Nutrition 0.000 description 6
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 6
• 229910052804 chromium Inorganic materials 0.000 description 6
• 238000002648 combination therapy Methods 0.000 description 6
• 238000010790 dilution Methods 0.000 description 6
• 239000012895 dilution Substances 0.000 description 6
• 210000003743 erythrocyte Anatomy 0.000 description 6
• 210000003297 immature b lymphocyte Anatomy 0.000 description 6
• 238000000338 in vitro Methods 0.000 description 6
• 229940047122 interleukins Drugs 0.000 description 6
• 239000013612 plasmid Substances 0.000 description 6
• 238000002560 therapeutic procedure Methods 0.000 description 6
• 241000283707 Capra Species 0.000 description 5
• 108020004414 DNA Proteins 0.000 description 5
• 241000196324 Embryophyta Species 0.000 description 5
• 206010061218 Inflammation Diseases 0.000 description 5
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 5
• 239000012980 RPMI-1640 medium Substances 0.000 description 5
• 239000002253 acid Substances 0.000 description 5
• 230000001419 dependent effect Effects 0.000 description 5
• 229940079593 drug Drugs 0.000 description 5
• 230000008030 elimination Effects 0.000 description 5
• 238000003379 elimination reaction Methods 0.000 description 5
• 238000005516 engineering process Methods 0.000 description 5
• 229940088598 enzyme Drugs 0.000 description 5
• 230000003053 immunization Effects 0.000 description 5
• 238000002649 immunization Methods 0.000 description 5
• 238000012544 monitoring process Methods 0.000 description 5
• 230000009257 reactivity Effects 0.000 description 5
• 230000009467 reduction Effects 0.000 description 5
• 239000011780 sodium chloride Substances 0.000 description 5
• 239000000243 solution Substances 0.000 description 5
• 241000894007 species Species 0.000 description 5
• 210000000130 stem cell Anatomy 0.000 description 5
• 238000002054 transplantation Methods 0.000 description 5
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
• 101150043916 Cd52 gene Proteins 0.000 description 4
• 108020004705 Codon Proteins 0.000 description 4
• 239000004471 Glycine Substances 0.000 description 4
• 101500025815 Homo sapiens Bri23 peptide Proteins 0.000 description 4
• 101500027322 Homo sapiens C-terminal peptide Proteins 0.000 description 4
• 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 4
• 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 4
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
• 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 4
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
• QWPXBEHQFHACTK-UHFFFAOYSA-N Maytansinol Natural products CN1C(=O)CC(O)C2(C)OC2C(C)C(OC(=O)N2)CC2(O)C(OC)C=CC=C(C)CC2=CC(OC)=C(Cl)C1=C2 QWPXBEHQFHACTK-UHFFFAOYSA-N 0.000 description 4
• 229930040373 Paraformaldehyde Natural products 0.000 description 4
• KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 4
• 238000011579 SCID mouse model Methods 0.000 description 4
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 4
• 239000004473 Threonine Substances 0.000 description 4
• 210000001015 abdomen Anatomy 0.000 description 4
• 150000001412 amines Chemical class 0.000 description 4
• 230000000890 antigenic effect Effects 0.000 description 4
• 229960002685 biotin Drugs 0.000 description 4
• 235000020958 biotin Nutrition 0.000 description 4
• 239000011616 biotin Substances 0.000 description 4
• 210000004970 cd4 cell Anatomy 0.000 description 4
• 230000001413 cellular effect Effects 0.000 description 4
• 230000008859 change Effects 0.000 description 4
• 238000006243 chemical reaction Methods 0.000 description 4
• 235000018417 cysteine Nutrition 0.000 description 4
• 230000001472 cytotoxic effect Effects 0.000 description 4
• 238000003745 diagnosis Methods 0.000 description 4
• 239000000839 emulsion Substances 0.000 description 4
• 125000000524 functional group Chemical group 0.000 description 4
• 108020001507 fusion proteins Proteins 0.000 description 4
• 230000001900 immune effect Effects 0.000 description 4
• 230000036039 immunity Effects 0.000 description 4
• 230000005847 immunogenicity Effects 0.000 description 4
• APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 4
• 230000004054 inflammatory process Effects 0.000 description 4
• 238000003780 insertion Methods 0.000 description 4
• 230000037431 insertion Effects 0.000 description 4
• 238000002372 labelling Methods 0.000 description 4
• 239000012528 membrane Substances 0.000 description 4
• 229920002866 paraformaldehyde Polymers 0.000 description 4
• 230000005298 paramagnetic effect Effects 0.000 description 4
• 239000008194 pharmaceutical composition Substances 0.000 description 4
• 239000000047 product Substances 0.000 description 4
• 238000011160 research Methods 0.000 description 4
• 229910052707 ruthenium Inorganic materials 0.000 description 4
• 239000000126 substance Substances 0.000 description 4
• 235000000346 sugar Nutrition 0.000 description 4
• 239000000725 suspension Substances 0.000 description 4
• 238000001890 transfection Methods 0.000 description 4
• PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 3
• 239000013607 AAV vector Substances 0.000 description 3
• 239000004475 Arginine Substances 0.000 description 3
• 108090001008 Avidin Proteins 0.000 description 3
• 241000894006 Bacteria Species 0.000 description 3
• 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 3
• VYZAMTAEIAYCRO-BJUDXGSMSA-N Chromium-51 Chemical compound [51Cr] VYZAMTAEIAYCRO-BJUDXGSMSA-N 0.000 description 3
• 108010029961 Filgrastim Proteins 0.000 description 3
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
• 108010031186 Glycoside Hydrolases Proteins 0.000 description 3
• 102000005744 Glycoside Hydrolases Human genes 0.000 description 3
• 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 3
• 241000238631 Hexapoda Species 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 3
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
• 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 3
• WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 description 3
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
• 238000012408 PCR amplification Methods 0.000 description 3
• 206010035226 Plasma cell myeloma Diseases 0.000 description 3
• 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 3
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
• 229940123237 Taxane Drugs 0.000 description 3
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
• 230000003110 anti-inflammatory effect Effects 0.000 description 3
• 230000000692 anti-sense effect Effects 0.000 description 3
• 229910052787 antimony Inorganic materials 0.000 description 3
• WATWJIUSRGPENY-UHFFFAOYSA-N antimony atom Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 description 3
• 230000001580 bacterial effect Effects 0.000 description 3
• 210000004899 c-terminal region Anatomy 0.000 description 3
• 238000012054 celltiter-glo Methods 0.000 description 3
• 125000003636 chemical group Chemical group 0.000 description 3
• 239000003153 chemical reaction reagent Substances 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 230000009918 complex formation Effects 0.000 description 3
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
• 231100000433 cytotoxic Toxicity 0.000 description 3
• 230000003013 cytotoxicity Effects 0.000 description 3
• 231100000135 cytotoxicity Toxicity 0.000 description 3
• 238000011161 development Methods 0.000 description 3
• 230000018109 developmental process Effects 0.000 description 3
• 208000035475 disorder Diseases 0.000 description 3
• 229960004679 doxorubicin Drugs 0.000 description 3
• 102000037865 fusion proteins Human genes 0.000 description 3
• 210000004602 germ cell Anatomy 0.000 description 3
• 238000006206 glycosylation reaction Methods 0.000 description 3
• 239000001963 growth medium Substances 0.000 description 3
• 230000036541 health Effects 0.000 description 3
• 229940055742 indium-111 Drugs 0.000 description 3
• 230000002757 inflammatory effect Effects 0.000 description 3
• 230000003993 interaction Effects 0.000 description 3
• 150000002500 ions Chemical class 0.000 description 3
• 238000002955 isolation Methods 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 239000011159 matrix material Substances 0.000 description 3
• 108020004999 messenger RNA Proteins 0.000 description 3
• 230000004048 modification Effects 0.000 description 3
• 238000012986 modification Methods 0.000 description 3
• 210000005087 mononuclear cell Anatomy 0.000 description 3
• 201000000050 myeloid neoplasm Diseases 0.000 description 3
• 239000013642 negative control Substances 0.000 description 3
• 239000013610 patient sample Substances 0.000 description 3
• 239000013641 positive control Substances 0.000 description 3
• 239000002243 precursor Substances 0.000 description 3
• 230000035755 proliferation Effects 0.000 description 3
• 238000000746 purification Methods 0.000 description 3
• 238000010188 recombinant method Methods 0.000 description 3
• 230000006798 recombination Effects 0.000 description 3
• 238000005215 recombination Methods 0.000 description 3
• 230000035945 sensitivity Effects 0.000 description 3
• 229910052717 sulfur Inorganic materials 0.000 description 3
• 239000011593 sulfur Substances 0.000 description 3
• 239000013589 supplement Substances 0.000 description 3
• 230000001225 therapeutic effect Effects 0.000 description 3
• 230000005747 tumor angiogenesis Effects 0.000 description 3
• 241000701161 unidentified adenovirus Species 0.000 description 3
• 239000004474 valine Substances 0.000 description 3
• 239000013603 viral vector Substances 0.000 description 3
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
• FGRBYDKOBBBPOI-UHFFFAOYSA-N 10,10-dioxo-2-[4-(N-phenylanilino)phenyl]thioxanthen-9-one Chemical compound O=C1c2ccccc2S(=O)(=O)c2ccc(cc12)-c1ccc(cc1)N(c1ccccc1)c1ccccc1 FGRBYDKOBBBPOI-UHFFFAOYSA-N 0.000 description 2
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
• KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
• 102000007698 Alcohol dehydrogenase Human genes 0.000 description 2
• 108010021809 Alcohol dehydrogenase Proteins 0.000 description 2
• 235000014469 Bacillus subtilis Nutrition 0.000 description 2
• 102100027207 CD27 antigen Human genes 0.000 description 2
• 102000012000 CXCR4 Receptors Human genes 0.000 description 2
• 108010061299 CXCR4 Receptors Proteins 0.000 description 2
• 108091026890 Coding region Proteins 0.000 description 2
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
• 108091035707 Consensus sequence Proteins 0.000 description 2
• 101710112752 Cytotoxin Proteins 0.000 description 2
• 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
• 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
• 101100481408 Danio rerio tie2 gene Proteins 0.000 description 2
• 108010053187 Diphtheria Toxin Proteins 0.000 description 2
• 102000016607 Diphtheria Toxin Human genes 0.000 description 2
• 206010061818 Disease progression Diseases 0.000 description 2
• 241000588724 Escherichia coli Species 0.000 description 2
• 108010087819 Fc receptors Proteins 0.000 description 2
• 102000009109 Fc receptors Human genes 0.000 description 2
• 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
• 208000009329 Graft vs Host Disease Diseases 0.000 description 2
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
• 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 2
• 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 2
• 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 2
• 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 2
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
• 102000002791 Interleukin-8B Receptors Human genes 0.000 description 2
• 108010018951 Interleukin-8B Receptors Proteins 0.000 description 2
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
• 102000003960 Ligases Human genes 0.000 description 2
• 108090000364 Ligases Proteins 0.000 description 2
• GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
• 208000005777 Lupus Nephritis Diseases 0.000 description 2
• BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
• 101100481410 Mus musculus Tek gene Proteins 0.000 description 2
• 201000002481 Myositis Diseases 0.000 description 2
• 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 2
• 244000061176 Nicotiana tabacum Species 0.000 description 2
• 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
• 108091034117 Oligonucleotide Proteins 0.000 description 2
• 239000004100 Oxytetracycline Substances 0.000 description 2
• 229930012538 Paclitaxel Natural products 0.000 description 2
• 241001494479 Pecora Species 0.000 description 2
• 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 2
• 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
• 108090000829 Ribosome Inactivating Proteins Proteins 0.000 description 2
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
• 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
• 238000012300 Sequence Analysis Methods 0.000 description 2
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
• 102220480895 Uncharacterized protein EXOC3-AS1_K53D_mutation Human genes 0.000 description 2
• RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
• 239000002671 adjuvant Substances 0.000 description 2
• 206010064930 age-related macular degeneration Diseases 0.000 description 2
• 125000001931 aliphatic group Chemical group 0.000 description 2
• 239000005557 antagonist Substances 0.000 description 2
• 239000003242 anti bacterial agent Substances 0.000 description 2
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
• 125000003118 aryl group Chemical group 0.000 description 2
• 229940009098 aspartate Drugs 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• 230000003115 biocidal effect Effects 0.000 description 2
• 230000015572 biosynthetic process Effects 0.000 description 2
• 210000000601 blood cell Anatomy 0.000 description 2
• 210000001124 body fluid Anatomy 0.000 description 2
• 239000010839 body fluid Substances 0.000 description 2
• 210000001185 bone marrow Anatomy 0.000 description 2
• 238000004587 chromatography analysis Methods 0.000 description 2
• GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 2
• 238000012875 competitive assay Methods 0.000 description 2
• 238000010276 construction Methods 0.000 description 2
• 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 2
• 231100000599 cytotoxic agent Toxicity 0.000 description 2
• 239000002619 cytotoxin Substances 0.000 description 2
• 238000007405 data analysis Methods 0.000 description 2
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
• 229960000975 daunorubicin Drugs 0.000 description 2
• 230000007423 decrease Effects 0.000 description 2
• 239000008121 dextrose Substances 0.000 description 2
• 230000005750 disease progression Effects 0.000 description 2
• 238000007877 drug screening Methods 0.000 description 2
• 230000009977 dual effect Effects 0.000 description 2
• 210000003527 eukaryotic cell Anatomy 0.000 description 2
• 230000001747 exhibiting effect Effects 0.000 description 2
• 229960004177 filgrastim Drugs 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• 239000007850 fluorescent dye Substances 0.000 description 2
• 238000012239 gene modification Methods 0.000 description 2
• 102000054767 gene variant Human genes 0.000 description 2
• 230000005017 genetic modification Effects 0.000 description 2
• 235000013617 genetically modified food Nutrition 0.000 description 2
• 210000004392 genitalia Anatomy 0.000 description 2
• 235000013922 glutamic acid Nutrition 0.000 description 2
• 239000004220 glutamic acid Substances 0.000 description 2
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
• 230000013595 glycosylation Effects 0.000 description 2
• 208000024908 graft versus host disease Diseases 0.000 description 2
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
• 210000005260 human cell Anatomy 0.000 description 2
• FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
• 150000002466 imines Chemical class 0.000 description 2
• 230000028993 immune response Effects 0.000 description 2
• 239000003018 immunosuppressive agent Substances 0.000 description 2
• 229940125721 immunosuppressive agent Drugs 0.000 description 2
• 238000010348 incorporation Methods 0.000 description 2
• 230000005764 inhibitory process Effects 0.000 description 2
• 238000007912 intraperitoneal administration Methods 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• 210000002540 macrophage Anatomy 0.000 description 2
• 208000002780 macular degeneration Diseases 0.000 description 2
• 238000012423 maintenance Methods 0.000 description 2
• 210000003071 memory t lymphocyte Anatomy 0.000 description 2
• 229960004857 mitomycin Drugs 0.000 description 2
• 238000001823 molecular biology technique Methods 0.000 description 2
• 208000004235 neutropenia Diseases 0.000 description 2
• 235000015097 nutrients Nutrition 0.000 description 2
• 210000000056 organ Anatomy 0.000 description 2
• 210000004789 organ system Anatomy 0.000 description 2
• 229960000625 oxytetracycline Drugs 0.000 description 2
• IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 2
• 235000019366 oxytetracycline Nutrition 0.000 description 2
• 229960001592 paclitaxel Drugs 0.000 description 2
• 239000008188 pellet Substances 0.000 description 2
• 238000002823 phage display Methods 0.000 description 2
• PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 2
• 229910052698 phosphorus Inorganic materials 0.000 description 2
• 239000011574 phosphorus Substances 0.000 description 2
• 239000000906 photoactive agent Substances 0.000 description 2
• YIQPUIGJQJDJOS-UHFFFAOYSA-N plerixafor Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 YIQPUIGJQJDJOS-UHFFFAOYSA-N 0.000 description 2
• 210000004986 primary T-cell Anatomy 0.000 description 2
• 238000007639 printing Methods 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
• 238000003127 radioimmunoassay Methods 0.000 description 2
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
• 238000011084 recovery Methods 0.000 description 2
• 230000010076 replication Effects 0.000 description 2
• 230000000717 retained effect Effects 0.000 description 2
• 102200090720 rs137852501 Human genes 0.000 description 2
• 102200087445 rs566961335 Human genes 0.000 description 2
• 238000012216 screening Methods 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 238000013207 serial dilution Methods 0.000 description 2
• 229960002930 sirolimus Drugs 0.000 description 2
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
• 239000007787 solid Substances 0.000 description 2
• 238000007619 statistical method Methods 0.000 description 2
• 238000011476 stem cell transplantation Methods 0.000 description 2
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• 229960002317 succinimide Drugs 0.000 description 2
• 208000011580 syndromic disease Diseases 0.000 description 2
• 238000003786 synthesis reaction Methods 0.000 description 2
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
• IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 2
• RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
• WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
• 238000004448 titration Methods 0.000 description 2
• 230000009261 transgenic effect Effects 0.000 description 2
• 238000011179 visual inspection Methods 0.000 description 2
• 238000012800 visualization Methods 0.000 description 2
• UVGHPGOONBRLCX-NJSLBKSFSA-N (2,5-dioxopyrrolidin-1-yl) 6-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]hexanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O UVGHPGOONBRLCX-NJSLBKSFSA-N 0.000 description 1
• WOWDZACBATWTAU-FEFUEGSOSA-N (2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-n-[(3r,4s,5s)-1-[(2s)-2-[(1r,2r)-3-[[(1s,2r)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-n,3-dimethylbutanamide Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C1=CC=CC=C1 WOWDZACBATWTAU-FEFUEGSOSA-N 0.000 description 1
• MHJJUOJOAJLYBS-ZBRNBAAYSA-N (2s)-2-aminopropanoic acid;(2s)-pyrrolidine-2-carboxylic acid Chemical compound C[C@H](N)C(O)=O.OC(=O)[C@@H]1CCCN1 MHJJUOJOAJLYBS-ZBRNBAAYSA-N 0.000 description 1
• FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
• KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
• SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
• VZXTWGWHSMCWGA-UHFFFAOYSA-N 1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(N)=N1 VZXTWGWHSMCWGA-UHFFFAOYSA-N 0.000 description 1
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
• FOWNDZJYGGTHRO-DKWTVANSSA-N 2-aminoacetic acid;(2s)-2-aminobutanedioic acid Chemical compound NCC(O)=O.OC(=O)[C@@H](N)CC(O)=O FOWNDZJYGGTHRO-DKWTVANSSA-N 0.000 description 1
• DJBRKGZFUXKLKO-UHFFFAOYSA-N 3-(pyridin-2-yldisulfanyl)propanoic acid Chemical compound OC(=O)CCSSC1=CC=CC=N1 DJBRKGZFUXKLKO-UHFFFAOYSA-N 0.000 description 1
• WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
• OOUPHXWHXYLQBK-UHFFFAOYSA-N 4-(pyridin-2-yldisulfanyl)pentanoic acid Chemical compound OC(=O)CCC(C)SSC1=CC=CC=N1 OOUPHXWHXYLQBK-UHFFFAOYSA-N 0.000 description 1
• IJJWOSAXNHWBPR-HUBLWGQQSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-hydrazinyl-6-oxohexyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 IJJWOSAXNHWBPR-HUBLWGQQSA-N 0.000 description 1
• GANZODCWZFAEGN-UHFFFAOYSA-N 5-mercapto-2-nitro-benzoic acid Chemical compound OC(=O)C1=CC(S)=CC=C1[N+]([O-])=O GANZODCWZFAEGN-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• 239000012114 Alexa Fluor 647 Substances 0.000 description 1
• 108010032595 Antibody Binding Sites Proteins 0.000 description 1
• 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
• 108020004491 Antisense DNA Proteins 0.000 description 1
• 108020005544 Antisense RNA Proteins 0.000 description 1
• 208000032467 Aplastic anaemia Diseases 0.000 description 1
• 101100257994 Arabidopsis thaliana FAB2 gene Proteins 0.000 description 1
• 102100024365 Arf-GAP domain and FG repeat-containing protein 1 Human genes 0.000 description 1
• 241000228257 Aspergillus sp. Species 0.000 description 1
• 206010055128 Autoimmune neutropenia Diseases 0.000 description 1
• 208000003950 B-cell lymphoma Diseases 0.000 description 1
• 244000063299 Bacillus subtilis Species 0.000 description 1
• 108010006654 Bleomycin Proteins 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• 208000026310 Breast neoplasm Diseases 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
• UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical class CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
• 108090000712 Cathepsin B Proteins 0.000 description 1
• 102000004225 Cathepsin B Human genes 0.000 description 1
• 102400001321 Cathepsin L Human genes 0.000 description 1
• 108090000624 Cathepsin L Proteins 0.000 description 1
• 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 1
• 206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 1
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
• 239000005944 Chlorpyrifos Substances 0.000 description 1
• 102000003858 Chymases Human genes 0.000 description 1
• 108090000227 Chymases Proteins 0.000 description 1
• 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
• 208000015943 Coeliac disease Diseases 0.000 description 1
• 102000029816 Collagenase Human genes 0.000 description 1
• 108060005980 Collagenase Proteins 0.000 description 1
• 206010009944 Colon cancer Diseases 0.000 description 1
• 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
• 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
• 241000195493 Cryptophyta Species 0.000 description 1
• 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 1
• 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 1
• 102000003909 Cyclin E Human genes 0.000 description 1
• 108090000257 Cyclin E Proteins 0.000 description 1
• 102100021906 Cyclin-O Human genes 0.000 description 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
• SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
• 238000001712 DNA sequencing Methods 0.000 description 1
• 108010092160 Dactinomycin Proteins 0.000 description 1
• 206010012689 Diabetic retinopathy Diseases 0.000 description 1
• 101100286286 Dictyostelium discoideum ipi gene Proteins 0.000 description 1
• 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
• 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
• 206010059866 Drug resistance Diseases 0.000 description 1
• YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
• 206010015150 Erythema Diseases 0.000 description 1
• 108090000371 Esterases Proteins 0.000 description 1
• 241000206602 Eukaryota Species 0.000 description 1
• 208000031969 Eye Hemorrhage Diseases 0.000 description 1
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
• PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
• 102000002702 GPI-Linked Proteins Human genes 0.000 description 1
• 108010043685 GPI-Linked Proteins Proteins 0.000 description 1
• GYHNNYVSQQEPJS-OIOBTWANSA-N Gallium-67 Chemical compound [67Ga] GYHNNYVSQQEPJS-OIOBTWANSA-N 0.000 description 1
• 208000032612 Glial tumor Diseases 0.000 description 1
• 206010018338 Glioma Diseases 0.000 description 1
• 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
• 239000007995 HEPES buffer Substances 0.000 description 1
• 101150009006 HIS3 gene Proteins 0.000 description 1
• 102000006354 HLA-DR Antigens Human genes 0.000 description 1
• 108010058597 HLA-DR Antigens Proteins 0.000 description 1
• 239000012981 Hank's balanced salt solution Substances 0.000 description 1
• 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
• 208000032843 Hemorrhage Diseases 0.000 description 1
• 208000028523 Hereditary Complement Deficiency disease Diseases 0.000 description 1
• 101710160287 Heterochromatin protein 1 Proteins 0.000 description 1
• 101000897441 Homo sapiens Cyclin-O Proteins 0.000 description 1
• 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
• 101001043807 Homo sapiens Interleukin-7 Proteins 0.000 description 1
• 101001018097 Homo sapiens L-selectin Proteins 0.000 description 1
• 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
• 101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 description 1
• 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 1
• 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
• UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
• 101150106931 IFNG gene Proteins 0.000 description 1
• 102000026633 IL6 Human genes 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
• 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
• 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
• 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
• 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
• 102100034343 Integrase Human genes 0.000 description 1
• 102100022297 Integrin alpha-X Human genes 0.000 description 1
• 108010005716 Interferon beta-1a Proteins 0.000 description 1
• 102000006992 Interferon-alpha Human genes 0.000 description 1
• 108010047761 Interferon-alpha Proteins 0.000 description 1
• 108010002350 Interleukin-2 Proteins 0.000 description 1
• 102000000588 Interleukin-2 Human genes 0.000 description 1
• 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 description 1
• 108090000978 Interleukin-4 Proteins 0.000 description 1
• 102400000704 Intracellular domain 1 Human genes 0.000 description 1
• 101800001559 Intracellular domain 1 Proteins 0.000 description 1
• UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
• 241000235058 Komagataella pastoris Species 0.000 description 1
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
• 102100033467 L-selectin Human genes 0.000 description 1
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• 241000209499 Lemna Species 0.000 description 1
• 244000207740 Lemna minor Species 0.000 description 1
• 235000006439 Lemna minor Nutrition 0.000 description 1
• 108010062867 Lenograstim Proteins 0.000 description 1
• 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 1
• 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
• 206010050551 Lupus-like syndrome Diseases 0.000 description 1
• 206010025327 Lymphopenia Diseases 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 102000018697 Membrane Proteins Human genes 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical group CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
• VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
• 229930192392 Mitomycin Natural products 0.000 description 1
• 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
• 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 1
• 101100370002 Mus musculus Tnfsf14 gene Proteins 0.000 description 1
• 108010021466 Mutant Proteins Proteins 0.000 description 1
• 102000008300 Mutant Proteins Human genes 0.000 description 1
• NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
• 229930193140 Neomycin Natural products 0.000 description 1
• 241000221961 Neurospora crassa Species 0.000 description 1
• 238000010222 PCR analysis Methods 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 108090000526 Papain Proteins 0.000 description 1
• 102000057297 Pepsin A Human genes 0.000 description 1
• 108090000284 Pepsin A Proteins 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 229920009405 Polyvinylidenefluoride (PVDF) Film Polymers 0.000 description 1
• 235000001855 Portulaca oleracea Nutrition 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 101710180313 Protease 3 Proteins 0.000 description 1
• 101710180012 Protease 7 Proteins 0.000 description 1
• 208000003670 Pure Red-Cell Aplasia Diseases 0.000 description 1
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
• 108020004511 Recombinant DNA Proteins 0.000 description 1
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
• 101100394989 Rhodopseudomonas palustris (strain ATCC BAA-98 / CGA009) hisI gene Proteins 0.000 description 1
• 108010039491 Ricin Proteins 0.000 description 1
• 108010084592 Saporins Proteins 0.000 description 1
• 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
• 206010039710 Scleroderma Diseases 0.000 description 1
• 208000034189 Sclerosis Diseases 0.000 description 1
• BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
• 101000865057 Thermococcus litoralis DNA polymerase Proteins 0.000 description 1
• 108010022394 Threonine synthase Proteins 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
• 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
• 102000011117 Transforming Growth Factor beta2 Human genes 0.000 description 1
• 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
• 101800000304 Transforming growth factor beta-2 Proteins 0.000 description 1
• 108090000097 Transforming growth factor beta-3 Proteins 0.000 description 1
• 102000056172 Transforming growth factor beta-3 Human genes 0.000 description 1
• 102000004142 Trypsin Human genes 0.000 description 1
• 108090000631 Trypsin Proteins 0.000 description 1
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
• 206010046851 Uveitis Diseases 0.000 description 1
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
• 241000700605 Viruses Species 0.000 description 1
• QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
• CUJRVFIICFDLGR-UHFFFAOYSA-N acetylacetonate Chemical compound CC(=O)[CH-]C(C)=O CUJRVFIICFDLGR-UHFFFAOYSA-N 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 238000001261 affinity purification Methods 0.000 description 1
• 238000012867 alanine scanning Methods 0.000 description 1
• 230000001476 alcoholic effect Effects 0.000 description 1
• 150000001299 aldehydes Chemical group 0.000 description 1
• 229940100198 alkylating agent Drugs 0.000 description 1
• 239000002168 alkylating agent Substances 0.000 description 1
• 230000000735 allogeneic effect Effects 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 1
• 229940025084 amphetamine Drugs 0.000 description 1
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
• 229960000723 ampicillin Drugs 0.000 description 1
• 238000004873 anchoring Methods 0.000 description 1
• 229940045799 anthracyclines and related substance Drugs 0.000 description 1
• 230000000340 anti-metabolite Effects 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 230000005875 antibody response Effects 0.000 description 1
• 229940100197 antimetabolite Drugs 0.000 description 1
• 239000002256 antimetabolite Substances 0.000 description 1
• 239000002246 antineoplastic agent Substances 0.000 description 1
• 239000003816 antisense DNA Substances 0.000 description 1
• 230000001640 apoptogenic effect Effects 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
• 229910052785 arsenic Inorganic materials 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
• 150000001540 azides Chemical class 0.000 description 1
• 239000011324 bead Substances 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 230000000740 bleeding effect Effects 0.000 description 1
• 229960001561 bleomycin Drugs 0.000 description 1
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 235000008429 bread Nutrition 0.000 description 1
• 210000000481 breast Anatomy 0.000 description 1
• 230000003139 buffering effect Effects 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 229910052799 carbon Inorganic materials 0.000 description 1
• 229960005243 carmustine Drugs 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 239000013592 cell lysate Substances 0.000 description 1
• 230000011748 cell maturation Effects 0.000 description 1
• 230000012292 cell migration Effects 0.000 description 1
• 239000006285 cell suspension Substances 0.000 description 1
• 230000005890 cell-mediated cytotoxicity Effects 0.000 description 1
• 108091092328 cellular RNA Proteins 0.000 description 1
• 208000011235 central nervous system lupus Diseases 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 229960004630 chlorambucil Drugs 0.000 description 1
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
• SURLGNKAQXKNSP-DBLYXWCISA-N chlorin Chemical compound C\1=C/2\N/C(=C\C3=N/C(=C\C=4NC(/C=C\5/C=CC/1=N/5)=CC=4)/C=C3)/CC\2 SURLGNKAQXKNSP-DBLYXWCISA-N 0.000 description 1
• 239000000460 chlorine Substances 0.000 description 1
• 229910052801 chlorine Inorganic materials 0.000 description 1
• SBPBAQFWLVIOKP-UHFFFAOYSA-N chlorpyrifos Chemical compound CCOP(=S)(OCC)OC1=NC(Cl)=C(Cl)C=C1Cl SBPBAQFWLVIOKP-UHFFFAOYSA-N 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• 210000003040 circulating cell Anatomy 0.000 description 1
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
• 229960004316 cisplatin Drugs 0.000 description 1
• 238000010367 cloning Methods 0.000 description 1
• 239000010941 cobalt Substances 0.000 description 1
• 229910017052 cobalt Inorganic materials 0.000 description 1
• 206010009887 colitis Diseases 0.000 description 1
• 229960002424 collagenase Drugs 0.000 description 1
• 230000002860 competitive effect Effects 0.000 description 1
• 201000002388 complement deficiency Diseases 0.000 description 1
• 230000004154 complement system Effects 0.000 description 1
• 239000003184 complementary RNA Substances 0.000 description 1
• 238000004590 computer program Methods 0.000 description 1
• 239000003636 conditioned culture medium Substances 0.000 description 1
• 230000003750 conditioning effect Effects 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 238000005336 cracking Methods 0.000 description 1
• 230000009260 cross reactivity Effects 0.000 description 1
• 229960004397 cyclophosphamide Drugs 0.000 description 1
• 229960000684 cytarabine Drugs 0.000 description 1
• 229940127089 cytotoxic agent Drugs 0.000 description 1
• 229960000640 dactinomycin Drugs 0.000 description 1
• 230000009615 deamination Effects 0.000 description 1
• 238000006481 deamination reaction Methods 0.000 description 1
• 125000006612 decyloxy group Chemical group 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 210000004443 dendritic cell Anatomy 0.000 description 1
• CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• 238000002405 diagnostic procedure Methods 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• 102000004419 dihydrofolate reductase Human genes 0.000 description 1
• 238000006471 dimerization reaction Methods 0.000 description 1
• 230000009266 disease activity Effects 0.000 description 1
• 238000007876 drug discovery Methods 0.000 description 1
• 201000004997 drug-induced lupus erythematosus Diseases 0.000 description 1
• 238000004043 dyeing Methods 0.000 description 1
• 230000002526 effect on cardiovascular system Effects 0.000 description 1
• 238000001378 electrochemiluminescence detection Methods 0.000 description 1
• 239000003792 electrolyte Substances 0.000 description 1
• 238000004520 electroporation Methods 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
• 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
• 210000000918 epididymis Anatomy 0.000 description 1
• 201000010063 epididymitis Diseases 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
• 230000000763 evoking effect Effects 0.000 description 1
• 210000000416 exudates and transudate Anatomy 0.000 description 1
• 229960002949 fluorouracil Drugs 0.000 description 1
• 229940014144 folate Drugs 0.000 description 1
• 235000019152 folic acid Nutrition 0.000 description 1
• 239000011724 folic acid Substances 0.000 description 1
• 238000009472 formulation Methods 0.000 description 1
• 230000002538 fungal effect Effects 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 238000002523 gelfiltration Methods 0.000 description 1
• 238000012637 gene transfection Methods 0.000 description 1
• 230000036252 glycation Effects 0.000 description 1
• 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 229910052736 halogen Inorganic materials 0.000 description 1
• 150000002367 halogens Chemical group 0.000 description 1
• 201000005787 hematologic cancer Diseases 0.000 description 1
• 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
• 208000006750 hematuria Diseases 0.000 description 1
• 125000005842 heteroatom Chemical group 0.000 description 1
• FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 102000049265 human CDR1 Human genes 0.000 description 1
• 102000044888 human CDR2 Human genes 0.000 description 1
• 102000052622 human IL7 Human genes 0.000 description 1
• 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
• MEXHSPXMLCGNJI-UHFFFAOYSA-N hydrazine prop-1-ene Chemical compound NN.CC=C MEXHSPXMLCGNJI-UHFFFAOYSA-N 0.000 description 1
• 229910052739 hydrogen Inorganic materials 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• 210000000987 immune system Anatomy 0.000 description 1
• 208000026278 immune system disease Diseases 0.000 description 1
• 230000002163 immunogen Effects 0.000 description 1
• 230000002998 immunogenetic effect Effects 0.000 description 1
• 238000003364 immunohistochemistry Methods 0.000 description 1
• 230000001976 improved effect Effects 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 238000001727 in vivo Methods 0.000 description 1
• 239000000411 inducer Substances 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 230000006749 inflammatory damage Effects 0.000 description 1
• 208000027866 inflammatory disease Diseases 0.000 description 1
• 230000010354 integration Effects 0.000 description 1
• 229960004461 interferon beta-1a Drugs 0.000 description 1
• 208000028774 intestinal disease Diseases 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 229910052742 iron Inorganic materials 0.000 description 1
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
• 229960000310 isoleucine Drugs 0.000 description 1
• YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
• 229960002618 lenograstim Drugs 0.000 description 1
• 229940087875 leukine Drugs 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 229960002247 lomustine Drugs 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 201000005202 lung cancer Diseases 0.000 description 1
• 208000020816 lung neoplasm Diseases 0.000 description 1
• 230000001926 lymphatic effect Effects 0.000 description 1
• 231100001023 lymphopenia Toxicity 0.000 description 1
• 238000002595 magnetic resonance imaging Methods 0.000 description 1
• 238000007885 magnetic separation Methods 0.000 description 1
• 230000003211 malignant effect Effects 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
• 229960001924 melphalan Drugs 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
• CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
• 229960005485 mitobronitol Drugs 0.000 description 1
• 229940074923 mozobil Drugs 0.000 description 1
• 231100000350 mutagenesis Toxicity 0.000 description 1
• RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
• 229960004866 mycophenolate mofetil Drugs 0.000 description 1
• 229960000951 mycophenolic acid Drugs 0.000 description 1
• HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
• YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
• OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
• 210000000581 natural killer T-cell Anatomy 0.000 description 1
• 239000006199 nebulizer Substances 0.000 description 1
• 230000010807 negative regulation of binding Effects 0.000 description 1
• 229960004927 neomycin Drugs 0.000 description 1
• 206010057887 neonatal lupus erythematosus Diseases 0.000 description 1
• 229940029345 neupogen Drugs 0.000 description 1
• 230000007658 neurological function Effects 0.000 description 1
• 238000006386 neutralization reaction Methods 0.000 description 1
• 239000000346 nonvolatile oil Substances 0.000 description 1
• 229920001542 oligosaccharide Polymers 0.000 description 1
• 150000002482 oligosaccharides Chemical class 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 235000019834 papain Nutrition 0.000 description 1
• 229940055729 papain Drugs 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 229940111202 pepsin Drugs 0.000 description 1
• 238000003359 percent control normalization Methods 0.000 description 1
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 description 1
• 229960002169 plerixafor Drugs 0.000 description 1
• 229960003171 plicamycin Drugs 0.000 description 1
• 108700028325 pokeweed antiviral Proteins 0.000 description 1
• 208000005987 polymyositis Diseases 0.000 description 1
• RKCAIXNGYQCCAL-UHFFFAOYSA-N porphin Chemical compound N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 RKCAIXNGYQCCAL-UHFFFAOYSA-N 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 150000003141 primary amines Chemical class 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
• 235000019833 protease Nutrition 0.000 description 1
• 238000000159 protein binding assay Methods 0.000 description 1
• 201000001474 proteinuria Diseases 0.000 description 1
• 230000017854 proteolysis Effects 0.000 description 1
• 229950010131 puromycin Drugs 0.000 description 1
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 150000003254 radicals Chemical class 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 210000000664 rectum Anatomy 0.000 description 1
• 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 210000005000 reproductive tract Anatomy 0.000 description 1
• 230000004044 response Effects 0.000 description 1
• 230000001177 retroviral effect Effects 0.000 description 1
• 238000010839 reverse transcription Methods 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 238000002473 ribonucleic acid immunoprecipitation Methods 0.000 description 1
• 150000003839 salts Chemical class 0.000 description 1
• 108010038379 sargramostim Proteins 0.000 description 1
• 238000009738 saturating Methods 0.000 description 1
• 230000002000 scavenging effect Effects 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 230000028327 secretion Effects 0.000 description 1
• 229910052711 selenium Inorganic materials 0.000 description 1
• 239000011669 selenium Substances 0.000 description 1
• 238000002864 sequence alignment Methods 0.000 description 1
• 238000012163 sequencing technique Methods 0.000 description 1
• 238000002741 site-directed mutagenesis Methods 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
• 239000002904 solvent Substances 0.000 description 1
• 210000000278 spinal cord Anatomy 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 230000003637 steroidlike Effects 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 229960005322 streptomycin Drugs 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 229940014800 succinic anhydride Drugs 0.000 description 1
• NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
• 229960001940 sulfasalazine Drugs 0.000 description 1
• NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• 229910021653 sulphate ion Inorganic materials 0.000 description 1
• 231100000617 superantigen Toxicity 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 208000024891 symptom Diseases 0.000 description 1
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
• 125000004149 thio group Chemical group *S* 0.000 description 1
• CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 1
• 229940113082 thymine Drugs 0.000 description 1
• 230000000451 tissue damage Effects 0.000 description 1
• 231100000827 tissue damage Toxicity 0.000 description 1
• 230000017423 tissue regeneration Effects 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 125000005490 tosylate group Chemical group 0.000 description 1
• 238000013518 transcription Methods 0.000 description 1
• 230000035897 transcription Effects 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 238000010361 transduction Methods 0.000 description 1
• 230000026683 transduction Effects 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 108010042974 transforming growth factor beta4 Proteins 0.000 description 1
• 238000013519 translation Methods 0.000 description 1
• 239000012588 trypsin Substances 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 241000701447 unidentified baculovirus Species 0.000 description 1
• 241001515965 unidentified phage Species 0.000 description 1
• 238000011144 upstream manufacturing Methods 0.000 description 1
• 229910052720 vanadium Inorganic materials 0.000 description 1
• 210000001177 vas deferen Anatomy 0.000 description 1
• 101150067041 vas gene Proteins 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 229960003048 vinblastine Drugs 0.000 description 1
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
• 229960004528 vincristine Drugs 0.000 description 1
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
• QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
• 235000005282 vitamin D3 Nutrition 0.000 description 1
• 239000011647 vitamin D3 Substances 0.000 description 1
• 229940021056 vitamin d3 Drugs 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 238000001262 western blot Methods 0.000 description 1
• 210000005253 yeast cell Anatomy 0.000 description 1